Akero Therapeutics, an early stage biotech developing therapies for NASH and other metabolic diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The South San Francisco, CA-based company was founded in 2017 and plans to list on the Nasdaq under the symbol AKRO. Akero Therapeutics filed confidentially on January 17, 2019. J.P. Morgan, Jefferies, Evercore ISI and Roth Capital are the joint bookrunners on the deal. No pricing terms were disclosed.
